This was the stock's second consecutive day of gains.

In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks discussed by Jim Cramer with insights on the DeepSeek AI sell-off. On the day that ...

In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other stocks. In his recent appearance on CNBC’s Squawk on the Street, Jim Cramer started ...

In a report released yesterday, David Toung from Argus Research maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The company’s shares opened today at $129.75.

The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter ...

Good morning and thank you for standing by. Welcome to Abbott’s Fourth Quarter 2024 Earnings Conference Call. All participants will be able to listen only until the question-and-answer portion ...

(Reuters) - Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device launches and growing demand for its glucose monitors to offset a ...

In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks expected to post impressive earnings this week. The earnings season is in full flow ...

The S&P 500 briefly hit 6,100 points on Wednesday, reaching a fresh all-time high as Wall Street embraced a powerful mix of strong corporate earnings and President Donald Trump's bold $500 billion ...

(RTTNews) - Abbott Laboratories (ABT) revealed a profit for its fourth quarter that increased from last year in line with the Street estimates. The company's bottom line totaled $9.229 billion ...

Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device launches and growing demand for its glucose monitors to offset a hit ...

(Reuters) - Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated medtech-related procedures to boost demand for its devices, including ...